Stratagene Revenue Grows 16% In Second Quarter; Strong Growth For QPCR And Mutagenesis Product Lines; Gain On Asset Sale Partially Offsets Hycor Merger Costs
10/19/2005 5:11:09 PM
Stratagene Corp. (Nasdaq:STGN), a developer, manufacturer and marketer of specialized life science research and immunodiagnostic products, today released financial results for the second quarter ended June 30, 2004. Stratagene was a privately held company until June 2, 2004, when it merged with Hycor Biomedical Inc. (formerly Nasdaq:HYBD) with Hycor surviving as a wholly owned subsidiary of Stratagene. Stratagene's second quarter and first half 2004 results include the historical results of Stratagene combined with the results of Hycor from the effective date of the merger through June 30, 2004.
comments powered by